SELLAS Life Sciences Group Inc (NASDAQ:SLS) price on Wednesday, July 02, rose 1.92% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.12.
A look at the stock’s price movement, the close in the last trading session was $2.08. Turning to its 52-week performance, $2.22 and $0.77 were the 52-week high and 52-week low respectively. Overall, SLS moved 34.18% over the past month.
SELLAS Life Sciences Group Inc’s market cap currently stands at around $211.53 million, with investors looking forward to this quarter’s earnings report slated for in August.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SLS is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend SLS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SLS’s current price about 22.05% and 27.27% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 65.80, while 7-day volatility ratio is 12.37% and 8.26% in the 30-day chart. Further, SELLAS Life Sciences Group Inc (SLS) has a beta value of 2.30. Analysts have given the company’s stock an average 52-week price target of $2.8, forecast between a low of $2.4 and high of $3.2. Looking at the price targets, the low is -13.21% off current price level while to achieve the yearly target high, price needs to move -50.94%. Nonetheless, investors will most likely welcome a -32.08% jump to $2.8 which is the analysts’ median price.
If we refocus on SELLAS Life Sciences Group Inc (NASDAQ:SLS), historical trading data shows that trading volumes averaged 2.65 million over the past 3 months. The company’s latest data on shares outstanding shows there are 99.78 million shares.
The 2.11% of SELLAS Life Sciences Group Inc’s shares are in the hands of company insiders while institutional holders own 14.33% of the company’s shares. Current price change has pushed the stock 78.15% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SLS stock continues to rise going into the next quarter.
